SCHEMBL4671635

SCHEMBL4671635

CC(C)(C)OC(=O)NC1(C2CNC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
GAA P10253 3/20 0.38
MEN1 O00255 2/20 0.38
MAPK1 P28482 1/20 0.38
EPHX1 P07099 1/20 0.34
EPHX2 P34913 1/20 0.34
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HCRTR2 O43614 1/20 0.33
ALDH1A1 P00352 1/20 0.33
BTK Q06187 1/20 0.33
CACNA1H O95180 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8570166 0.88 KMT2A (0.35) KMT2AGAAMEN1MAPK1EPHX1
SCHEMBL2082309 0.88 KMT2A (0.35) KMT2AGAAMEN1MAPK1EPHX1
SCHEMBL2082308 0.88 KMT2A (0.35) KMT2AGAAMEN1MAPK1EPHX1
SCHEMBL25370190 0.85 PSEN1 (0.34) KMT2AGAAMEN1MAPK1EPHX1
Oxalic Acid SCHEMBL2267135 0.84 BTK (0.33) KMT2AGAAMEN1MAPK1PSEN1
SCHEMBL2082222 0.82 PSEN1 (0.36) KMT2AGAAMEN1MAPK1EPHX1
SCHEMBL2082224 0.82 PSEN1 (0.36) KMT2AGAAMEN1MAPK1EPHX1
SCHEMBL4918795 0.81 MEN1 (0.38) KMT2AGAAMEN1MAPK1EPHX2
SCHEMBL7517321 0.81 PSEN1 (0.35) KMT2AGAAMEN1MAPK1EPHX1
SCHEMBL21335536 0.81 MEN1 (0.39) KMT2AGAAMEN1MAPK1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436667-B1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2026-01-21 EP disclosed
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2025-01-09 US disclosed
EP-4436667-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2024-10-02 EP disclosed
CN-118201916-A Piperazinylsulfonylaryl compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-06-14 CN disclosed
US-11806346-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2023-11-07 US disclosed
WO-2023072794-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-05-04 WO disclosed
EP-4149937-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI Foundation, Inc. (US) 2023-03-22 EP disclosed
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. 2022-12-29 US disclosed
EP-1304329-B1 Pyridonecarboxylic acid derivatives and their use as antibacterial agents DAIICHI SANKYO CO LTD (JP) 2008-10-15 EP disclosed
EP-1304329-B1 Pyridonecarboxylic acid derivatives and their use as antibacterial agents DAIICHI SANKYO CO LTD (JP) 2008-10-15 EP disclosed
EP-1304329-A2 Pyridonecarboxylic acid derivatives and their use as antibacterial agents DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-23 EP disclosed
US-5849757-A Pyridonecarboxylic acid derivatives substituted by a bicyclic amino group as antibacterials DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-12-15 US disclosed
CN-1179155-A Heterocyclic compounds DAIICHI PHARMACEUTICLA CO LTD (JP) 1998-04-15 CN disclosed
EP-0807630-A1 HETEROCYCLIC COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS ABL1, Q6ZSR9, NQO2 KMT2A 435/4885GAA 2644/4885MEN1 3705/4885
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 KMT2A 1178/4885GAA 143/4885MEN1 4321/4885
US-11806346-B2 HTT modulators for treating Huntington's disease HTT, HYPK, ATXN2 KMT2A 1178/4885GAA 143/4885MEN1 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.